News
Glyconics awarded internationally recognised quality certification forthe development of its range of diagnostic medical devices
Innovative diagnostics company, Glyconics® has been awarded an internationally recognised quality certification for the design and development of its medical devices product range.
Following a review by BSI, one of the world’s leading notified bodies, Glyconics has been awarded ISO...
Drug Research
Major Pharma Companies, Including Novartis And Merck, Build Federated Learning Platform For Drug Discovery
Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Institut De Recherches Servier, Janssen, Merck, and Novartis — inked an agreement to build a shared platform called MELLODDY (Machine Learning Ledger Orchestration for Drug Discovery). In partnership with Nvidia, Owkin, and...
News
Nippon Express adds blockchain to global pharma supply networks
Nippon Express (NE) is in the process of developing pharmaceutical supply chain networks. NE says it will look to employ the digital technologies of IoT and blockchain to track logistics information end-to-end.
This will seek to optimise supply chains for...
News
Kuehne+Nagel Air Logistics invests in global vaccine distribution network
With the opening of airside pharma & healthcare hubs in Brussels, Belgium, and Johannesburg, South Africa, Kuehne+Nagel adds two strategic elements to its global GxP-certified network of temperature-controlled facilities for the distribution of vaccines and other pharma & healthcare...
News
BioNTech to Acquire GMP Manufacturing Site to Expand COVID-19 Vaccine Production Capacity in First Half 2021
BioNTech SE announced the signing of a share purchase agreement with Novartis AG, Basel / Switzerland to acquire their GMP certified manufacturing facility in Marburg, Germany. The manufacturing site will expand BioNTech’s COVID-19 vaccine production capacity by up to...
News
Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting
Eli Lilly and Company announced proof of concept data from an interim analysis of the BLAZE-1 clinical trial, showing a reduced rate of hospitalization for patients treated with LY-CoV555. The randomized, double-blind, placebo-controlled Phase 2 study evaluated LY-CoV555, a...
News
AstraZeneca acquires oral PCSK9 inhibitor programme from Dogma Therapeutics
AstraZeneca has entered into an agreement with Dogma Therapeutics to acquire its preclinical oral PCSK9 inhibitor programme. The Company aims to take the programme forward into clinical development for dyslipidaemia, or abnormal amount of lipids in the blood, and...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.